Business
PEXA.B: Sales and earnings fell, but strong equity and new funding support global expansion and R&D
PEXA.B: Sales and earnings fell, but strong equity and new funding support global expansion and R&D
About this update from Pexa Ab Class B
Net sales and earnings declined sharply year-over-year, but equity ratio remains strong. Recent capital raise, scientific recognition, and expanded global presence support ongoing transition from research to clinical applications.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.